ASCO: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer

At last year’s American Society of Clinical Oncology annual meeting, AstraZeneca posted Lynparza data that would eventually make it the first in its class to break into breast cancer. This time around, it’s trying to grab the same crown in prostate cancer.